| Title | Authors (identified) | Published In | Identifier(s) | Topic | Published Date | Match? |
|---|
| 0947 CLINICAL CHARACTERISTICS OF CHILDHOOD NARCOLEPSY FOLLOWING THE H1N1 PANDEMICS: PRELIMINARY DATA FROM THE PEDIATRIC WORKING GROUP OF THE SLEEP RESEARCH NETWORK | [1]N Simakajornboon, [2]C Melendres, [3]S Sheldon, [4]E Super, [5]K Naqvi, [6]J Brockbank, [7]R Beckerman, [8]R Amin, [9]J Lew, [10]B Malow, [11]C Marcus, [12]A Mason, [13]R Chervin, [14]L Kheirandish-Gozal, [15]E Mignot [Full author list] | Sleep [missing] | DOI: 10.1093/SLEEPJ/ZSX050.946 [ORCID]
| | 2017-04-28 | |
| Cost Offsets Associated With Rebif Use In First-Line Rrms: An Analysis Based on The Cochrane Collaboration Review And Real-World Persistence Data | [1]S L Wong, [2]R Fujii, [3]R Beckerman [Full author list] | Value in Health [missing] | DOI: 10.1016/J.JVAL.2015.09.2910 [ORCID]
| collaboration [missing] | 2015-10-20 | |
| Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries | [1]Z Younossi, [2]A Brown, [3]M Buti, [4]Stefano Fagiuoli, [5]S Mauss, [6]William Rosenberg, [7]L Serfaty, [8]A Srivastava, [9]N Smith, [10]M Stepanova, [11]R Beckerman [Full author list] | Journal of Viral Hepatitis [missing] | DOI: 10.1111/JVH.12483 [ORCID]
PubMed: 26482680 [ORCID]
| hepatitis C [missing]; Hepatitis C virus [missing]; eradication of infectious diseases [missing]; chronic hepatitis C [missing]; chronic hepatitis [missing] | 2015-10-20 | |
| Cost-Effectiveness of Ceritinib Versus Current Therapies for Chemotherapy-Experienced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients in Mexico. | [1]S Balu, [2]O Cerezo-Camacho, [3]N J Smith, [4]R Beckerman [Full author list] | Value in Health [missing] | DOI: 10.1016/J.JVAL.2015.09.261 [ORCID]
| ceritinib [missing] | 2015-10-20 | |
| Strategies To Overcome Hurdles In Hta Appraisals Amid Limitations Resulting From Single-Arm Trial Data | [1]A Xenakis, [2]R Beckerman [Full author list] | Value in Health [missing] | DOI: 10.1016/J.JVAL.2014.08.071 [ORCID]
PubMed: 27202600 [ORCID]
| | 2014-10-26 | |
| Best Practices and Key Challenges in Cost-Effectiveness Modelling of Multiple Sclerosis Therapies | [1]N Smith, [2]R Beckerman [Full author list] | Value in Health [missing] | DOI: 10.1016/J.JVAL.2014.08.540 [ORCID]
PubMed: 27203058 [ORCID]
| multiple sclerosis [missing] | 2014-10-26 | |
| Intact splenic function in cystic fibrosis | [1]N J Barrios, [2]M Kiernan, [3]R Beckerman, [4]S Davis [Full author list] | Journal of the National Medical Association [missing] | PubMed: 8040902 [ORCID]
| cystic fibrosis [missing] | 1994-04-01 | |
| Factor II (prothrombin) coagulant activity in immunoreactive protein: detection of vitamin K deficiency and liver disease in patients with cystic fibrosis | [1]J J Corrigan, [2]L M Taussig, [3]R Beckerman, [4]J S Wagener [Full author list] | The Journal of Pediatrics [missing] | DOI: 10.1016/S0022-3476(81)80468-4 [ORCID]
PubMed: 7252687 [ORCID]
| cystic fibrosis [missing]; (E)-phytonadione [missing]; liver disease [missing]; vitamin K deficiency [missing] | 1981-08-01 | |